(Q43671239)

25 November 2017

Serum potassium levels, CPK-MB and ECG in children suffering asthma treated with beclomethasone or beclomethasone-salmeterol (English)

1 reference

25 November 2017

1 reference

Del Río-Navarro BE

1

1 reference

25 November 2017

Sienra-Monge JJ

2

1 reference

25 November 2017

Alvarez-Amador M

3

1 reference

25 November 2017

Reyes-Ruiz N

4

1 reference

25 November 2017

Arévalo-Salas A

5

1 reference

25 November 2017

Berber A

6

1 reference

25 November 2017

1 January 2001

1 reference

Allergologia et Immunopathologia

25 November 2017

1 reference

25 November 2017

29

1 reference

25 November 2017

1

1 reference

25 November 2017

16-21

1 reference

A review of the current guidelines for allergic rhinitis and asthma

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Intravenous salbutamol in the treatment of status asthmaticus in children

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Potential masking effects of salmeterol on airway inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

The pharmacology of salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Inhaled corticosteroids: benefits and risks

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Effects of long term inhaled high dose beclomethasone dipropionate on adrenal function

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Myocardial specific creatine phosphokinase isoenzyme elevation in children with asthma treated with intravenous isoproterenol

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

The use of beta-agonists and the risk of death and near death from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Myocardial ischemia complicating the use of isoproterenol in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

An Electrocardiographic Pattern of Acute Myocardial Infarction Associated with Excessive Use of Aerosolized Isoproterenol

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Fatal myocardial toxicity during continuous infusion intravenous isoproterenol therapy of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Beta2-agonist induced ventricular dysrhythmias secondary to hyperexcitable conduction system in the absence of a long QT syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Short-term cardiovascular effects of salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Pathologic changes induced by 1-norepineprine: quantitative aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2801%2979010-6

7 January 2021

10.1016/S0301-0546(01)79010-6

Identifiers

DOI

1 reference

25 November 2017

1 reference